Intellia Therapeutics (NTLA) Payables (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Payables data on file, last reported at $18.8 million in Q1 2026.

• Payables for Q1 2026 came in at $18.8 million, up 52.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.8 million (up 52.05% YoY), and the FY2025 annual result was $20.3 million, up 38.82% from the prior year.
• Payables retreated to $18.8 million in Q1 2026 per NTLA's latest filing, from $20.3 million in the prior quarter.
• Over five years, Payables peaked at $20.3 million in Q4 2025 and troughed at $3.6 million in Q3 2023.
• A 5-year average of $11.3 million and a median of $11.6 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables jumped 269.97% in 2024, then slumped 47.91% in 2025.
• A 5-year view of Payables shows it stood at $5.2 million in 2022, then jumped by 44.59% to $7.5 million in 2023, then soared by 95.77% to $14.6 million in 2024, then surged by 38.82% to $20.3 million in 2025, then retreated by 7.17% to $18.8 million in 2026.
• Business Quant data shows NTLA's Payables at $18.8 million in Q1 2026, $20.3 million in Q4 2025, and $13.3 million in Q3 2025.